Introduction {#section5-2042018820938304}
============

Neuroendocrine neoplasms (NENs) are commonly considered as rare, but the latest actual incidence rate has increased by 6.4 times from 1973 (1.09 per 100,000) to 2012 (6.98 per 100,000), as reported by the Surveillance, Epidemiology, and End Results (SEER) program.^[@bibr1-2042018820938304]^

The 2019 World Health Organization classification system classified NENs of the gastrointestinal (GI) tract into three categories: neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs) and neuroendocrine--non-neuroendocrine neoplasm (MiNEN).^[@bibr2-2042018820938304]^ NETs are defined as well-differentiated neoplasms. NECs are poorly differentiated neoplasms, and MiNENs are defined as neoplasms having both the neuroendocrine and non-neuroendocrine components, each of which accounts for at least 30% of the tumor.^[@bibr2-2042018820938304]^

Both NECs and MiNENs are highly aggressive and rare.^[@bibr3-2042018820938304][@bibr4-2042018820938304]--[@bibr5-2042018820938304]^ However, few studies have been conducted on their prognosis, and the conclusions are ambiguous. La Rosa *et al.*^[@bibr6-2042018820938304]^ reported that patients with GI MiNENs generally had a better prognosis than patients with NECs. Both Lin *et al*.^[@bibr7-2042018820938304]^ and van der Veen A *et al*.^[@bibr8-2042018820938304]^ found that there was no statistically significant difference in prognosis between gastric MiNEN and gastric NEC patients, but La Rosa *et al*.^[@bibr9-2042018820938304]^ observed that gastric MiNEN has a better median overall survival (OS) than patients with pure NECs. As for the colon, the results are also varied.^[@bibr10-2042018820938304],[@bibr11-2042018820938304]^ In addition, NENs are recognized as a heterogeneous family with multiple biological and clinical behaviors.^[@bibr12-2042018820938304][@bibr13-2042018820938304]--[@bibr14-2042018820938304]^ Therefore, it is unclear whether the inconsistent prognostic results between NECs and MiNENs are due to the high heterogeneity of NENs or site-related clinical differences. The limited sample sizes used in these studies may be another reason.

This study retrospectively reviewed patients with pure NECs or MiNENs of the GI tract from 1975 to 2016 using nationally representative data from the SEER program. The aims of this study are to clarify whether the prognosis of NECs and MiNENs of the GI tract is similar and to explore the prognostic factors related to NECs and MiNENs, respectively.

Methods {#section6-2042018820938304}
=======

Study design {#section7-2042018820938304}
------------

Observational cross-sectional study.

Patients and data collection {#section8-2042018820938304}
----------------------------

Data were collected from the *SEER* program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) *SEER\*Stat Database*, including nine regions between the inception of the *SEER* program in 1975 until 31 December 2016, and 18 regions between the inception of the *SEER* program in 2000 until 31 December 2016, based on the November 2018 submission. The data used in this study were obtained from the *SEER* program by signing the *SEER* Research data Agreement form, a public open database.

Eligible patients were defined as MiNEN or NEC according to the *International Classification of Diseases for Oncology*, third edition (ICD-O-3) histology codes (8244/3, 8246/3) in the GI tract. Detailed information was collected for these patients, including age, sex, race, primary tumor site, ICD-O-3 histology/behavior, American Joint Committee on Cancer (AJCC) TNM Stage (seventh edition), whether or not surgical treatment was given, survival months and end status. According to the AJCC TNM staging system 7th edition, *T* status was determined by tumor size and extension, *N* status was determined by lymphatic metastasis, and *M* status was determined by distant metastasis. Data were then analyzed by tumor site, including the esophagus, stomach, small intestine (SI), cecum, appendix, colon, rectum, pancreas, liver, gallbladder, biliary tract (GB) and other GI sites.

Statistical analysis {#section9-2042018820938304}
--------------------

Data were entered into Excel data sheets and then analyzed with SPSS Statistics software for Windows, Version 25.0 (IBM Corp., Armonk, NY, USA) or GraphPad Prism v6.0c. Clinical and pathological features were expressed as median and range, absolute value or fractions. The *t*-test was used to compare the age difference between the MiNEN and NEC patients, and a chi-square test was performed to analyze the differences in sex distribution and AJCC stage distribution (I--III *versus* IV) between the MiNEN and NEC patients. The OS was calculated from the date of initial diagnosis to the date of death or last follow-up. A survival analysis was performed by applying the Kaplan--Meier analysis and log-rank test for comparison. A propensity matching analysis was used to analyze the survival difference between MiNEN and NEC in the appendix. Propensity scores were based on age, sex, race, stage and surgery, and these two groups were matched using a greedy approach with a caliper width of 0.02 standard deviation of the logit of the propensity score. Regarding the survival and prognostic factors of the patients with NEC or MiNEN, the hazard ratio (HR) and 95% confidence interval (CI) were calculated by applying the Cox proportional hazard regression analysis. Due to the limitation in sample sizes, esophageal MiNEN, pancreatic MiNEN and hepatic MiNEN were not further analyzed using the Cox proportional hazard regression analysis. *p* \< 0.05 was considered statistically significant.

Results {#section10-2042018820938304}
=======

Patient characteristics {#section11-2042018820938304}
-----------------------

A total of 12,878 patients diagnosed with NEC or MiNEN in the GI tract were collected using the *SEER* registers from 1975 to 2016. The clinical characteristics of these patients are as shown in [Table 1](#table1-2042018820938304){ref-type="table"}. The median age at diagnosis was 61.0 years (range: 4--98 years). Among the 12,878 patients, 6737 (52.31%) were male and 6141 (47.69%) were female. A total of 77.95% patients were White, 13.88% were Black and 7.15% represented others (American Indian/Alaskan Native and Asian/Pacific Islander).

###### 

Patient characteristics.

![](10.1177_2042018820938304-table1)

                   Total (*n*, %)   NEC             MiNEN
  ---------------- ---------------- --------------- -------------
  *n* (%)          12,878 (100)     12,160 (94.4)   718 (5.6)
  Age, years                                        
  Median (range)   61 (4--98)       61 (4--98)      60 (10--96)
  Sex, *n*, (%)                                     
  Male             6737 (52.31)     6364 (49.42)    373 (2.90)
  Female           6141 (47.69)     5796 (45.01)    345 (2.68)
  Race, *n* (%)                                     
  White            10,039 (77.95)   9457 (73.44)    582 (4.52)
  Black            1788 (13.88)     1704 (13.23)    84 (0.65)
  Other            921 (7.15)       873 (6.78)      48 (0.37)
  Unknown          130 (1.01)       126 (0.98)      4 (0.03)
  Stage, *n* (%)                                    
  I                1362 (10.58)     1338 (10.39)    24 (0.19)
  II               874 (6.79)       752 (5.84)      122 (0.95)
  III              1167 (9.06)      1083 (8.41)     84 (0.65)
  IV               2340 (18.17)     2238 (17.38)    102 (0.79)
  Unknown          949 (7.37)       943 (7.32)      6 (0.05)
  Blanks           6186 (48.04)     5806 (45.08)    380 (2.95)

MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasm; NEC, neuroendocrine carcinoma

Distribution and clinical characteristics of NEC and MiNEN of the GI tract {#section12-2042018820938304}
--------------------------------------------------------------------------

Among all the 12,878 patients, 12,160 (94.4%) were NEC patients and 718 (5.6%) were MiNEN patients ([Table 2](#table2-2042018820938304){ref-type="table"}). The top four most common sites of NEC in the GI tract were pancreas, SI, rectum, and stomach, accounting for almost three-quarters of all the cases ([Table 2](#table2-2042018820938304){ref-type="table"}). Among the MiNEN patients, the most common sites were appendix, cecum, colon, and rectum ([Table 2](#table2-2042018820938304){ref-type="table"}). When the GI tract was divided into foregut, midgut, and hindgut, the results indicated that NEC was most likely to occur in the foregut, whereas MiNEN was most likely to occur in the midgut ([Table 2](#table2-2042018820938304){ref-type="table"}).

###### 

Distribution of NEC and MiNEN of the GI tract by primary tumor site.

![](10.1177_2042018820938304-table2)

  ----------------------------------------------------------------------------
                                   Total\         NEC\            MiNEN\
                                   *n* (%)        *n* (%)         *n* (%)
  -------------------------------- -------------- --------------- ------------
  All cases, *n* (%)               12,878 (100)   12,160 (94.4)   718 (5.6)

   Esophagus                       200 (1.6)      196 (1.6)       4 (0.6)

   Stomach                         1052 (8.2)     1011 (8.3)      41 (5.7)

   Small intestine                 2536 (19.7)    2496 (20.5)     40 (5.6)

   Appendix                        829 (6.4)      432 (3.6)       397 (55.3)

   Cecum                           691 (5.4)      614 (5.0)       77 (10.7)

   Colon                           875 (6.8)      798 (6.6)       77 (10.7)

   Rectum                          1434 (11.1)    1376 (11.3)     58 (8.1)

   Pancreas                        4422 (34.3)    4416 (36.3)     6 (0.8)

   Liver                           240 (1.9)      240 (2.0)       0 (0.0)

   Gallbladder and biliary tract   305 (2.4)      288 (2.4)       17 (2.4)

   Other GI sites                  294 (2.3)      293 (2.4)       1 (0.1)

  Foregut                          6204 (48.2)    6139 (50.5)     65 (9.1)

  Midgut                           3981 (30.9)    3443 (28.3)     538 (74.9)

  Hindgut                          1854 (14.4)    1757 (14.4)     97 (13.5)

  Other                            839 (6.5)      821 (6.8)       18 (2.5)
  ----------------------------------------------------------------------------

GI, gastrointestinal; MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasm; NEC, neuroendocrine carcinoma

Overall, there was no significant difference in the mean age of diagnosis between NECs and MiNENs of the GI tract, except for the appendix \[[Figure 1(A)](#fig1-2042018820938304){ref-type="fig"}\]. The mean age at diagnosis of MiNENs was significantly higher than that of NECs in the appendix (57.30 ± 0.6301 *versus* 41.27 ± 0.8608, *p* \< 0.001) \[[Figure 1(A)](#fig1-2042018820938304){ref-type="fig"}\]. When all NENs were divided into foregut, midgut and hindgut, the results showed that the mean age of the NECs diagnosis in the foregut was significantly lower than that of MiNENs diagnosis (60.40 ± 0.1791 *versus* 65.42 ± 1.654, *p* = 0.0041) \[[Figure 1(B)](#fig1-2042018820938304){ref-type="fig"}\].

![Patient characteristics among NEC and MiNEN patients. (A) Age distribution of NEC and MiNEN per primary tumor site in the GI tract. (B) Age distribution of NEC and MiNEN in the foregut, midgut and hindgut. (C) Sex distribution of NEC and MiNEN per primary tumor site in the GI tract. (D) AJCC stage (I--III *versus* IV) distribution of NEC and MiNEN per primary tumor site in the GI tract.\
AJCC, American Joint Committee on Cancer; GB, gallbladder; GI, gastrointestinal; MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasm; NEC, neuroendocrine carcinoma; NS, not significant; SI, small intestine](10.1177_2042018820938304-fig1){#fig1-2042018820938304}

Regarding the ratio of males to females, there was no significant difference between the NEC and the MiNEN patients, except for the stomach and appendix \[[Figure 1(C)](#fig1-2042018820938304){ref-type="fig"}\]. The proportion of male patients with gastric NECs was higher than that of gastric MiNENs (52.42% *versus* 36.59%, *p* = 0.047), whereas for the appendix, the proportion of male patients with NECs was lower than that of MiNEN (35.42% *versus* 50.13%, *p* \< 0.0001) \[[Figure 1(C)](#fig1-2042018820938304){ref-type="fig"}\]. The proportion of the patients diagnosed at AJCC Stage I--III to AJCC Stage IV between the NEC and MiNEN patients was not significantly different except in the appendix and colon \[[Figure 1(D)](#fig1-2042018820938304){ref-type="fig"}\]. In the appendix, MiNEN was more likely to be diagnosed at a later stage (AJCC Stage IV) than NEC \[*p* \< 0.001; [Figure 1(D)](#fig1-2042018820938304){ref-type="fig"}\]. Conversely, in the colon, NEC was more likely to be diagnosed at a later stage than MiNEN \[*p* = 0.027; [Figure 1(D)](#fig1-2042018820938304){ref-type="fig"}\].

No survival difference between NEC and MiNEN in gastrointestinal tract except in the SI and appendix {#section13-2042018820938304}
----------------------------------------------------------------------------------------------------

[Figure 2](#fig2-2042018820938304){ref-type="fig"} depicts the results obtained from the Kaplan--Meier analysis. The median survival time was 107 and 92 months for NEC and MiNEN patients, respectively (*p* = 0.4215). The Kaplan--Meier survival analysis showed that there was no significant difference in the survival time between the esophageal NEC and esophageal MiNEN (OS: 35 months *versus* 9 months, *p* = 0.1598), gastric NEC and MiNEN (OS: 52 months *versus* 27 months, *p* = 0.2528), caecal NEC and MiNEN (OS: 21 months *versus* 34 months, *p* = 0.8023), colonic NEC and MiNEN (OS: 12 months *versus* 31 months, *p* = 0.0859), rectal NEC and MiNEN (OS: 244 months *versus* 176 months, *p* = 0.9295), NEC and MiNEN in the GB (OS: 15 months *versus* 14 months, *p* = 0.5591). The median survival of SI NEC was 130 months, in contrast to that of SI MiNEN, which was 61 months (*p* \< 0.0001). In the appendix, the prognosis of MiNEN was significantly worse than that of NEC (*p* \< 0.0001).

When all NENs were classified into foregut, midgut and hindgut, the results demonstrated that the MiNENs had a worse prognosis than the NEC in the midgut (*p* = 0.0012), while there were no significant differences in the prognosis between the foregut NEC and MiNEN (*p* = 0.1623), as well as between the hindgut NEC and MiNEN (*p* = 0.9160).

![Kaplan--Meier curves for overall survival in patients with NEC and MiNEN at each site of the GI tract. (A) Total, (B) esophagus, (C) stomach, (D) small intestine, (E) cecum, (F) appendix, (G) colon, (H) rectum, (I) gallbladder and biliary tract, (J) other GI sites. Kaplan--Meier curves for overall survival in patients with NEC and MiNEN in the foregut (K), midgut (L) and hindgut (M).\
GI, gastrointestinal; MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasm; NEC, neuroendocrine carcinoma; OS, overall survival](10.1177_2042018820938304-fig2){#fig2-2042018820938304}

Prognostic factors for pure NEC and MiNEN {#section14-2042018820938304}
-----------------------------------------

Univariate and multivariate Cox regression analyses showed that age (*p* \< 0.0001), male sex (*p \< 0.01*), TNM stage (*p* \< 0.0001) and not receiving surgical treatment (*p* \< 0.0001) were negative prognostic factors for overall survival in patients with NEC in the GI tract. Age (*p =* 0.003), TNM stage (*p* \< 0.0001) and not receiving surgical treatment (*p* \< 0.001) were negative prognostic factors for overall survival in patients with MiNEN in the GI tract ([Table 3](#table3-2042018820938304){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analyses on prognostic baseline factors for survival in patients with NEC or MiNEN in the GI tract.

![](10.1177_2042018820938304-table3)

  NEC          MiNEN                                                                                                                                                                     
  ------------ ------------------------- ---------------------- ---------------------- ---------------------- ------------------------- ---------------------- ------------------------- ------------
  Age, years                             1.8248E-110                                   1.281E-22                                        2.0872E-7                                        0.003
   \<55        1                                                1                                             1                                                1                         
   ⩾55         1.939 (1.830--2.055)      1.699 (1.528--1.889)   1.907 (1.495--2.434)   1.782 (1.214--2.616)                                                                              
  Sex                                    3.4193E-11                                    0.002361                                         0.261                                            
   Female      1                                                1                                             1                                                                          
   Male        1.185 (1.127--1.246)                             1.149 (1.051--1.257)                          0.885 (0.714--1.096)                                                       
  Race                                   0.006                                         0.789                                            0.159                                            
   White       1                         0.002                  1                                             1                                                                          
   Black       0.891 (0.827--0.960)      0.002                  0.957 (0.840--1.089)   0.504                  1.058 (0.771--1.452)      0.726                                            
   Other       0.930 (0.840--1.029)      0.162                  0.979 (0.822--1.166)   0.814                  0.591 (0.339--1.031)      0.064                                            
  Stage                                  2.5922E-259                                   1.0068E-96                                       3.4039E-24                                       2.3131E-19
   I           1                                                1                                             1                                                1                         
   II          2.513 (1.970--3.204)      1.0954E-13             2.363 (1.851--3.016)   4.8708E-12             3.424 (0.458--25.585)     0.230                  3.271 (0.438--24.449)     0.248
   III         2.875 (2.300--3.594)      1.7609E-20             2.936 (2.345--3.676)   5.7121E-21             15.178 (2.082--110.625)   0.007                  16.034 (2.199--116.882)   0.006
   IV          12.188 (10.046--14.787)   7.5871E-142            6.619 (5.414--8.094)   8.5176E-76             44.413 (6.162--320.107)   0.000167               37.907 (5.235--274.500)   0.000320
  Surgery                                \<0.0001                                      1.4547E-104                                      2.479E-11                                        0.000347
   Yes         1                                                1                                             1                                                1                         
   No          4.015 (3.802--4.239)      3.336 (2.992--3.719)                          3.024 (2.185--4.186)                             2.358 (1.474--3.773)                             

CI, confidence interval; GI, gastrointestinal; HR, hazard ratio; MiNEN, mixed neuroendocrine-non-neuroendocrine neoplasm; NEC, neuroendocrine carcinoma

Univariate and multivariate Cox regression analyses, including age, sex, race, TNM staging and whether or not surgical treatment was given, were conducted according to tumor site to evaluate the prognostic factors related to the prognosis of NEC and MiNEN further. The Cox regression analyses for the esophageal NEC indicated that both TNM Stages III and IV had a worse survival than TNM Stage I ([Supplemental Material Table 1](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304); *p =* 0.044 and *p* = 0.002). In the stomach, Cox regression analyses for NEC revealed that age ⩾ 55 years (*p* = 0.047), TNM Stages III and IV (*p* \< 0.0001) and not receiving surgical treatment (*p* \< 0.0001) were poor prognostic factors, and there were no effective prognostic factors for MiNEN ([Supplemental Table 2](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)). In SI, age ⩾ 55 years (*p* \< 0.0001), TNM Stage IV (*p* = 0.002) and not receiving surgical treatment (*p* = 0.016) were identified as negative prognostic factors for survival in patients with NEC using multivariate Cox regression analysis, and age ⩾ 55 years (*p* = 0.017) was identified as a negative prognosis factor for survival in patients with MiNEN using univariate Cox regression analysis ([Supplemental Table 3](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)). In the cecum, both TNM Stage IV (*p* \< 0.0001) and not receiving surgical treatment (*p* = 0.001) were identified as negative prognosis factors for NEC from the multivariate Cox regression analysis results, and only TNM Stage IV (*p =* 0.011) was identified as the negative prognostic factor for survival in patients with MiNEN using multivariate Cox regression analysis ([Supplemental Table 4](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)). In the appendix, both age and TNM Stage IV were identified as negative prognostic factors for survival in patients with both NEC and MiNEN based on Cox regression analyses ([Supplemental Table 5](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)). In the colon, age ⩾ 55 years (*p* = 0.011), TNM Stages III and IV (*p* = 0.015 and *p* \< 0.0001) and not receiving surgical treatment (*p =* 0.001) were poor prognostic factors for NEC from the multivariate Cox regression analysis results, and only TNM Stage IV (*p* \< 0.0001) was identified as a negative prognostic factor for MiNEN using univariate Cox regression analysis ([Supplemental Table 6](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)). In the rectum, age ⩾ 55 years (*p* = 0.004), race (*p* = 0.018), TNM stage (*p* \< 0.0001) and not receiving surgical treatment (*p* \< 0.001) were independent prognostic factors for NEC using multivariate Cox regression analysis, and not receiving surgical treatment (*p =* 0.007) was identified as a negative prognostic factor for survival in patients with MiNEN from the univariate Cox regression analysis results ([Supplemental Table 7](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)). In the pancreatic NEC, age ⩾ 55 years (*p* \< 0.0001), TNM Stages II--IV (*p* \< 0.001) and not receiving surgical treatment (*p* \< 0.0001) were poor prognostic factors ([Supplemental Table 8](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)). In hepatic NEC, sex (*p* = 0.047) and race (*p* = 0.022) were identified as independent prognostic factors for survival ([Supplemental Table 9](http://journals.sagepub.com/doi/suppl/10.1177/2042018820938304)).

Discussion {#section15-2042018820938304}
==========

Both NEC and MiNEN are malignant tumors and have neuroendocrine neoplasm components; however, it remained unknown whether both have the same prognosis. Therefore, in this study, we reviewed and compared the prognostic differences between NEC and MiNEN and summarized their prognostic factors. To the best of our knowledge, this investigation is the most extensive study on the comparison of the characteristics and survival between NEC or MiNEN patients in the GI tract by tumor site.

NECs were mostly found in the colon, pancreas and SI based on a dataset of 5509 NEC patients in the GI tract, according to Dasari *et al*.^[@bibr1-2042018820938304]^ In this retrospective study, we found that the top three most common sites of NEC were the pancreas, SI and rectum, which is generally consistent with the findings of previous studies. MiNENs have been found in the esophagus, stomach, appendix, colon, rectum and biliary tract,^[@bibr15-2042018820938304][@bibr16-2042018820938304][@bibr17-2042018820938304][@bibr18-2042018820938304][@bibr19-2042018820938304][@bibr20-2042018820938304][@bibr21-2042018820938304][@bibr22-2042018820938304][@bibr23-2042018820938304]--[@bibr24-2042018820938304]^ but most reports were case reports and small case series, and few reports had long-term follow-up data in the literature.^[@bibr21-2042018820938304]^ We observed that the most common site of MiNEN was appendix, and the MiNENs in the esophagus, stomach, pancreas and biliary tract were rare, accounting for less than 10% of the total number of MiNENs.

So far, most of the studies on the prognostic differences between NEC and MiNEN were small sample-size studies and the conclusions were quite different. A retrospective study regarding the clinicopathologic features and prognosis of NEC and MiNEN of the esophagus included 40 patients and reported that esophageal NEC is an aggressive tumor, and patients with MiNEN have a better outcome.^[@bibr25-2042018820938304]^ By analyzing 51 pure NEC patients and 15 MiNEN patients, La Rosa *et al*.^[@bibr9-2042018820938304]^ observed that gastric MiNEN has a better median OS than patients with pure NECs. Conversely, a study from South Korea, by comparing the prognosis between 47 gastric NEC patients and 10 MiNEN patients, revealed that no survival difference was observed between them.^[@bibr26-2042018820938304]^ The results of the two studies on survival differences between colonic NECs and MiNENs are also different.^[@bibr10-2042018820938304],[@bibr11-2042018820938304]^ In addition, two studies on appendiceal MiNEN found that MiNEN is a more aggressive clinical entity than both goblet cell carcinoid of the appendix and carcinoid tumors of the appendix.^[@bibr21-2042018820938304],[@bibr27-2042018820938304]^ La Rosa *et al.* and Klöppel *et al*.^[@bibr6-2042018820938304],[@bibr28-2042018820938304]^ considered that some clinical differences between NECs and MiNENs might be site-related.

In our study, we retrieved 12,878 patients from *SEER* and further analyzed the survival difference between NEC and MiNEN both as a whole and by the primary tumor sites. Overall, no significant difference was observed in the prognosis between NEC and MiNEN in the GI tract. When we further compared the prognosis according to the primary tumor sites, we observed different site-related results in the survival time between NEC and MiNEN. In the esophagus, stomach, cecum, colon, rectum and GB, patients with MiNEN had a similar survival time in comparison with patients with NEC. However, in the SI and appendix, we found OS for MiNEN to be significantly shorter than that of NEC. Our results suggest that the prognostic differences between NEC and MiNEN are site-related.

There are several limitations of this study. First, although data on more than 10,000 patients were collected from the *SEER* database in this study, the included cases may not wholly represent the characteristics of the entire NEN population because the included population were mainly White, and the number of MiNENs in some specific sites was very small. Second, the population in the *SEER* database is primarily Medicare/Medicaid based and, thus, may have a bias. Third, although *SEER* provides detailed clinical information of the NEN patients, we found that the lack of detailed treatment factors, such as chemotherapy, quality of surgery, and systemic treatment, could confound the results. Fourth, there is a possible immortal time bias due to different treatments over time.

In general, patients with GI MiNEN have a similar median OS to patients with pure NEC, while in the appendix and SI, MiNEN is a more aggressive entity than pure NEC. Therefore, there is a need to pay more attention to patients with MiNEN in the SI and appendix and monitor their management more closely.

Supplemental Material {#section16-2042018820938304}
=====================
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